Friday, April 22, 2005

Say Hello to Edelman

The public relations guard has changed at the California stem cell agency.

Red Gate Communications, which handled PR for Prop. 71 and some of the early months of the agency's existence, has resigned the account. Edelman, the world’s largest independent public relations firm with 1,800 employees, has been retained.


Also on board as a state employee is Nicole R. Pagano, senior communications specialist, and formerly with the Brookings Institution in Washington, D.C. She is listed at the top of the two-person contact list on the CIRM web site. Below her is Adam Silber, who is head of Edelman's Sacramento office.

In response to questions, Fiona Hutton, president of Red Communications in Studio City, CA., said in an email, “Red Gate Communications recently resigned its representation of the California stem cell agency. As you might imagine, we are very proud of the communications and outreach efforts we so successfully orchestrated during Prop 71 and during the first few, formative (albeit challenging) months of the Institute. It has been our pleasure to have worked closely with the Institute and so many passionate stakeholders throughout both these efforts. The firm continues its stem cell research expertise and advocacy in other regions throughout the nation.”

The change at CIRM came suddenly nearly two weeks ago, leading to a certain amount of speculation and rumor. The agency put out no advisory to the media about the change, merely altering the contact names on its web site.

Only on Thursday did the agency confirm that Edelman had been hired. That was after multiple queries by this blog to the agency and, on Wednesday, to the chief of staff nationally for Edelman


In an email, Pagano said, “CIRM has engaged Edelman to assist the Institute in fulfilling its public education and media relations duties, and was selected after a competitive search process.

“The mission of the Institute is to make grants and provide loans to advance stem cell research. Edelman will assist the Institute in its mission by making its progress as transparent and understandable as possible – both to the voters of California who have funded it and to the medical research communities who share its commitment.”


Pagano did not respond to questions concerning Edelman's compensation or whether it was required to file any economic disclosures in connection with possible conflicts of interest.

The contract is not insignificant. Red Gate's contract provided for as much as $70,000 for work from Jan. 18 to April 18, which was its entire term. While it is not yet known how much Red Gate was paid, the $70,000 figure is not unreasonable given the scope of the work, which went far beyond fielding phone calls from reporters. If Edelman is working under similar terms, a year contract could mean $250,000-$300,000 compensation. However, the agency now has on staff at least one fulltime person, Pagano, so that could affect Edelman's package.

Skilled public relations, information dissemination and public education are valuable assets for any organization. It is even more important for CIRM, which has virtually no track record and which is delving into areas new to medicine and public policy as well as to the public at large. However, PR is dependent on reality. To build a great reputation and keep faith with the people of California, CIRM must demonstrate accomplishment and accountability.

The Edelman Blog and Government PR

Richard Edelman, the main man at the PR firm for the California stem cell agency, writes his own blog on the public relations business.

Recently he commented on the flap about federal government contracts for public relations. He said the PR business basically is “accused of foisting government propaganda on the American people, in direct violation of the law.”

To counter that sort of bad PR, he told his readers (others in the business) “let's start by revealing the size of our US government contracts.” Edelman also said, “The industry “ should commit to providing full disclosure on exactly what we do for Government contracts.”

“It is possible that this level of transparency will make it less attractive to the US Government to hire PR agencies. So be it,” Edelman blogged

Other advice for PR people “trying to adapt to a fast-changing environment.”
“We have to be operating in parallel universes, continuing to do a great job with traditional media, while engaging with new media,” Edelman wrote.

“We should help our clients create original content, and advise them to engender conversations on-line but be honest about our inability to control outcomes. We must be on top of the breaking news in companies, because news is being filled by the person who has the newest information. The coverage of tsunami initially came from survivors with cell phones or mini-cams, and delivered across the Web. Our tone in new media must reflect the different expectations of the audience, which is to demand authenticity, individuality and transparency.”

Thursday, April 21, 2005

Ho-Hum. Stem Cell Measures Approved

California legislative action on measures to tighten oversight of the state's stem agency attracted little interest in the media today.

Reporter Laura Kurtzman of the San Jose Mercury News appeared to be the only reporter who attended Thursday's meeting of the Senate Health Committee and wrote a story on the legislation, which was approved 10-0.

The Associated Press filed a story, but did not actually attend the session. Instead it relied on a statement from the office of the Sen. Deborah Ortiz, D-Sacramento, chair of the committee.

It is not uncommon for news outlets to write stories on such a basis when they deem the subjects not to be compelling. In this case, passage of the measure seemed assured since it was co-authored by Ortiz and the Republican vice-chair of the committee, George Runner of Antelope Valley.

Kurtzman fleshed out her story with additional reporting. She wrote,“The proposal would require the California Institute for Regenerative Medicine, which was created by Proposition 71, to abide by National Institutes of Health standards that were recently revised to bar employees from holding biotech or pharmaceutical stocks.”

“While refusing formally to take a position, representatives of the Institute for Regenerative Medicine said in interviews after the hearing that the rules were too restrictive. The head of the National Institutes of Health's human stem-cell program recently cited the (NIH) rules in announcing his retirement.”

Kurtzman quoted Ortiz as saying, “There is a higher level of accountability. This is a hybrid. This is a new model. In the end, it is the taxpayers who either benefit or lose in that equation.''

The AP story appeared on the web sites of the San Diego Union Tribune, San Francisco Chronicle and The Sacramento Bee, but not on the Los Angeles Times. Here is a link to the AP story and a link to the press releases on the two measures, which now move to the appropriations committee.

Wednesday, April 20, 2005

The Stem Cell Agency Just Says No

The California stem cell agency has yanked one of its Oversight Committee members from a public panel on implementation of Prop. 71, reportedly because it did not want to share the same platform with one of its critics.

As a result the conference, sponsored by Political Pulse in Sacramento, was cancelled.

CIRM's withdrawal left some in Sacramento bemused, given the agency's pledge of openness. One insider said the action was “very unfortunate, and does not bode well for the ICOC creating an open dialogue with the public, much less maintaining public confidence in the institute.”

Political Pulse is an independent source of Capitol items and has been around for 20 years. It scheduled the teleconference for April 27, promising that it would explore issues and information about the agency and its startup progress.


Scheduled to be heard at the teleconference event were State Sen. Deborah Ortiz, D-Sacramento; Dr. David Gollaher, president of the California Healthcare Institute of La Jolla; Marcy Darnovsky, associate executive director of the Center for Genetics and Society in Oakland, and Dr. Phyllis Preciado of Fresno, a member of the Oversight Committee.


It was Darnovsky's presence that apparently triggered the withdrawal of Preciado. Darnovsky's organization has been a vociferous critic of the stem cell agency on issues ranging from the stem cell medical questions to conflicts of interest.

Political Pulse did not respond to questions about the cancellation nor did CIRM, including whether this was a onetime action or reflected an agency policy.

Coming Up

On Thursday, we will take a look at the leavings from today's legislative hearings on measures to tighten oversight of the California stem cell agency. Be sure to check the item.

Tuesday, April 19, 2005

Looking for Analysis in the Right Places

Searching for a clear, straight forward overview of the legislation to tighten controls over the California stem cell agency?

The best bet is the legislative staff analysis which can be found on the Web(
here and here). It states what the law is, what is being changed and summarizes some of the issues. It doesn't, however, deal with Robert Klein's contention that the legislation is thwarting the will of the people, a dangerous political argument that goes beyond the purview of staff analysis.

The analysis of that dubious assertion can be found in a couple of items on this blog: “The Fallacy of the Will of the People” (3-23) and “Will California Vote Again on Stem Cell Research” (4-15).

Ortiz Drops Superovulation Moratorium

The leading stem cell research supporter in the California legislature is dropping a proposed moratorium on superovulation in her legislation to tighten oversight of the state's new stem cell agency.

Instead Sen. Deborah Ortiz, D-Sacramento, is going to ask the agency to fund a study of the impact of hyperovulation on women's bodies, said Hallye Jordan, director of communications for the lawmaker, who is chair of the Senate Health Committee.

Ortiz has teamed with a conservative Republican, Sen. George Runner of Antelope Valley, to co-author measures, including a proposed constitutional amendment, to require the State Auditor to audit Prop. 71 expenditures. The legislation would also require written informed consent procedures and limits on compensation for women who wish to donate eggs for medical research, among other things.

The legislation will be considered by the Senate Health Committee in Sacramento Wednesday afternoon. For more on this, see the item on this blog April 15, “Will California Vote Again on Stem Cell Research?”

Monday, April 18, 2005

Stem Cell Snippets: Dudes to Brownback

"Simply the most cost efficient” -- Sacramento Mayor Heather Fargo and UC Davis Chancellor Larry Vanderhoef plumped for selection of the Capitol City as stem cell central in a piece in The Sacramento Bee. “Home prices here are 27 percent less than in Los Angeles, 40 percent less than in San Diego and roughly half those in the San Francisco Bay Area,” they wrote. But their main point was that Sacramento is “the place where the people come to be heard,” where the “public conducts the public business.”

“Dude, you obviously don't know Emeryville!” -- Inclusion of the little city of 10,000 among the finalists for the permanent stem cell agency HQ left some folks in Los Angeles mystified. Columnist Chip Johnson of the San Francisco Chronicle
explained why, at least in his view. Among the reasons is a certain vision. “In the early 1980s, when few people had ever heard the term biotechnology,” Johnson wrote, “Emeryville gave the thumbs up to three UC Berkeley professors who wanted to open a lab in Emeryville. Those men, William Rutter, Edward Penhoet and Pablo Valenzuela, are the founders of Chiron Corp., one of the largest biotech firms in the world.” Penhoet is now vice chairman of the stem cell agency.

Now Hiring – Just posted on the stem cell agency's Web site are new hiring plans. Over the next six to nine months, it will bring on as many as 15 full time scientists who will be responsible for reviewing and managing its scientific programs. The agency is looking for a strong background in basic or clinical biomedical research, including a Ph.D. and/or an M.D., post-doctoral experience as well as relevant experience. More information is available here, but it doesn't tell job seekers they might have to live in Sacramento to afford housing and commute to the pricey Bay Area.

Brownback's BanLocal Liberty, the blog of the Center for Local Government at the Claremont Institute, notes how doings in Washington, D.C., could affect this state. “More threatening” than lawsuits against CIRM in California “is United States Senator Sam Brownback's bill to ban all human cloning, even if the cloned embryo is prevented from growing in a womb, as California law requires. The CIRM plans to spend lots of its $3 billion to research human cloning in this manner.”

All Laid Out – The stem cell agency has posted its approved conflict of interest policies on its web site. The Sacramento Bee commented critically on the standards for working group members. “Unfortunately, institute leaders have proposed a deeply flawed policy, one that doesn't pass the good-government smell test....Institute staff will instruct the reviewers to recuse themselves from considering any grant decisions with which they have a conflict. No disclosure forms will be required. As a result, the institute's staff will have no ready mechanism for ensuring that reviewers are acting ethically. Nor will the public.”

Friday, April 15, 2005

Will California Vote Again on Stem Cell Research?

Plan your stem cell calendar around next Wednesday's California legislative hearings on efforts to tighten controls over the state's stem cell agency, including a proposal that could become a statewide referendum on its performance.

Sen. Deborah Ortiz, chair of the Senate Health Committee, has authored both a bill and a proposed constitutional amendment that will come before her committee in Sacramento. Co-authoring the proposals by the Sacramento Democrat is conservative Republican Sen. George Runner of Antelope Valley, vice chair of the committee.


Ortiz supported Prop. 71. Runner opposed it. She proposed her measures “to maintain the public’s confidence, the integrity of this important research and California’s significant financial investment.”

“We must make sure meetings are open to public scrutiny, strict conflict-of-interest and economic disclosure standards are developed, patients’ rights are protected and the state receives a fair financial return on its generous investment,” she said.

Runner said, “The voters of California did not vote for Proposition 71 so that biomedical companies get a windfall of billions of tax dollars with little or no accountability. It’s critical that we establish the highest ethical conflict of interest standards, true operating transparency, and a direct benefit to Californians from their $6 billion investment.”

Ortiz introduced an early version of the legislation last December. It was toughened up following an informational hearing in March. Robert Klein, the chairman of the stem cell agency and the prime mover on the ballot measure, refused to appear before the hearing of both the Assembly and Senate Health committees, despite the fact that he is a state employee, albeit one who is independently wealthy.

While promising publicly to cooperate with the committees, he lobbied behind-the-scenes to have the hearing put off. His efforts also came at the same time that his allied nonprofit organization, Cures for California, sent out emails across the country to generate pressure on the legislature. The messages solicited recipients (presumably disease sufferers) to send emails to the Legislature or call seeking postponement of the legislative hearing because of the possibility it would generate bad press.

Legislators later privately called Klein his “own worst enemy” and described him as a “meglomaniac and liar(see Roiling Undercurrents 3/16 on this blog).”

The Health Committee seems certain to approve the bill and constitutional amendment, but that is only the first step on their legislative journey. Should the constitutional amendment win approval of the legislature, it must appear on a statewide ballot. If it does, it is likely to become a referendum on all that the agency has done – not just the contents of the measure.

Such a ballot fight would give stem cell opponents a huge, fresh target, one that is likely to bring in major national anti-research campaigns from the Christian right, among other players. That would be a serious distraction for the agency, to put it mildly.

The task facing Klein is to scuttle early on at least the constitutional amendment. If he fails, it will gain momentum and become increasingly difficult to kill.

Here are links to the bill and the constitutional amendment. Earlier blogs on the legislation and related matters included: Robert Klein: The Missing Man (3/15), “Roiling Undercurrents (3/16), Litany of Losses (3/17).
---------------
We welcome and will publish comments on CIRM or the failings of this blog. Please send your comments to djensen@californiastemcellreport.blogspot.com.

Thursday, April 14, 2005

Added Link on HQ Story

Here is the link to the San Jose Mercury News post mortem on how the city blew its bid by failing to mind the details.

The Devil and Decisions

A couple of lessons are to be learned from the business this week regarding the permanent headquarters of the California stem cell agency.

One is the appropriate way to present complex material for quick and sound decisions. Second is the old cliché about the devil in details.

The background agenda material for the site selection subcommittee was very late in coming. But when it did come it was clear, complete and concise. The decision points were identified and the rationale was coherent. We suspect that was largely the influence of the State Department of General Services, which has eons of experience in making such presentations. By contrast, the stem cell agency's agendas are often muddled and confused, which bog down the meetings and make it difficult to make good decisions.

Failure to mind the details savaged the losers in the bidding process for the headquarters. One wonders how supposedly accomplished executives and their staffs managed to omit simple documents from their applications. It is not as if the selection panel overlooked the missing information. Calls were made to the losers to verify that they failed to send in their coupons, so to speak.

The fiasco does bring to mind March's meeting of the Oversight Committee and the fracas over the missing information on the presidential selection criteria(see Fumbling the CEO Search April 4 on this blog).

The tale of the permanent headquarters is not yet finished. There is talk of appeals by the disgruntled to the Oversight Committee. Ratings could change as a result of site visits and other considerations. One can only imagine the lobbying and political pressure that will come the way of the Oversight Committee members, who probably should take their phones off the hook.

Here are links to this morning's stories on the HQ affair: Sacramento Bee, San Francisco Chronicle, San Diego Union Tribune.

Wednesday, April 13, 2005

International Stem Cell Soiree

The city that wins the bid for the permanent headquarters for the California stem cell agency can look forward to an annual, high-powered international stem cell conference that would generate the kind of attention that makes city leaders salivate.

The plan was tucked away in the criteria for the headquarters, along with a couple of other tidbits illuminating the agency's thinking and expectations.

“The CIRM is currently the single most important source of stem cell research funding in the world,” the document said. “As such, it will be a draw for researchers and clinicians around the world for conferences and other knowledge sharing activities. CIRM leadership plans to hold at least one international conference a year.”

“Additionally, the CIRM plans to host numerous events to gather government officials and patient advocacy personnel together on topics relevant to the CIRM mission,” which means, among other things, a bunch of business for meeting planners.

The agency also said it will be busy tending its political fences in Sacramento, regardless whether that city wins the bid. “CIRM business in Sacramento—meeting with elected officials and legislators as well as government personnel—has already required numerous staff trips in the last several months. This travel frequency is estimated to continue.”

Coming up on Thursday will be a look at the leavings from today's meeting on HQ location. Here are links to Wednesday's stories on the HQ: San Francisco Chronicle, Sacramento Bee, San Diego Union Tribune, Los Angeles Times, Los Angeles Daily News, San Jose Mercury News.

Tuesday, April 12, 2005

Finalists for the HQ

The finalists for the permanent headquarters for the California stem cell agency are San Francisco, Emeryville, Sacramento and San Diego.

The
San Francisco Business Times said San Francisco scored highest in a point system that examined eight categories, such as cost, the availability of no- or-low cost hotel and meeting space and the size of the surrounding biomedical community.

San Francisco chalked up a total of 158 points followed by Sacramento with 133, San Diego with 116 and Emeryville with 113.

The stem cell agency posted details of ratings sometime this afternoon on its web site in the
agenda of the subcommittee considering the matter. That theoretically allowed members of the subcommittee less than 24 hours to study the issue before their meeting.

The agency did not respond to queries about whether the subcommittee members had been given copies any earlier.

Big Money Moving In

The Wall Street Journal today described how large companies are quietly moving into the stem cell business. One of the reasons is interest generated as a result of the California stem cell agency.

Here are some excerpts from the article by Antonio Regalado:

“Stepping gingerly into a politically charged arena for the first time, some large companies in the U.S. are pursuing plans to study stem cells drawn from early-stage human embryos.”

“Among companies that have initiated research programs or have plans to are Becton, Dickinson & Co., Invitrogen Corp., Johnson & Johnson, General Electric Co. and the U.S.-based research operations of Swiss drug giant Novartis AG. Their interests range from using the cells to test drugs to developing new transplant treatments.”

“A survey by The Wall Street Journal of 12 of the world's largest drug firms by sales, as well as leading U.S. biotechnology concerns and medical-device makers, found several previously undisclosed research programs involving human embryonic stem cells. But many companies said they weren't using stem cells, and several had policies forbidding the research.

“In no case is a major U.S. company working directly with human embryos. Instead they are turning to small companies and universities to obtain supplies of the cells. Johnson & Johnson, for instance, is backing cutting-edge research on the cells at a biotechnology company in California. Becton Dickinson received supplies from the University of Wisconsin. Other companies declined to say where they obtained cells or where they planned to get them.”

The Yuck Factor

Imagine an ape that laughs like Phyllis Diller. Imagine a sheep with human arms growing from its body, a fantasy – for now -- on the edge of stem cell research.

Such creatures are called chimeras, a word derived from the monstrous beast of Greek mythology -- part lion, part serpent and part goat.


Author Jamie Shreeve wrote about the 2005 versions of chimeras in the New York Sunday Times Magazine. Some of his examples are located here in the west, such as experiments involving implantation of human stem cells in sheep.

Esmail Zanjani, a hematologist in the College of Agriculture, Biotechnology and Natural Resources at the University of Nevada at Reno, says he has sheep with livers that are 40 percent humanized. Shreeve, in discussing the ethics of such situations, asks the rhetorical question, “What if, instead of internal human organs, Zanjani's sheep sported recognizably human parts on the outside -- human limbs or genitals, for instance, ready for transplant should the need arise?”

Shreeve's article also discusses experiments by Irving Weissman in California. “Several years ago, Weissman and his colleagues at Stanford and at StemCells Inc., a private company he helped to found, transplanted human neural stem cells into the brains of newborn mice.” Weissman is now considering the possibility of making a mouse brain composed entirely of human neurons.

Taking it a step further, Shreeve wrote about possibilities involving primates. '''One could imagine that if you took a human embryonic midbrain and spliced it into a developing chimpanzee, you could get a chimp with many of our automatic vocalizations,''' says Terrence Deacon, a biological anthropologist at the University of California at Berkeley and a member of the Johns Hopkins committee. 'It wouldn't be able to talk. But it might laugh or sob, instead of pant-hoot.'''

Which brings us to the possibility of an ape that laughs like Phyllis Diller” and what some in the stem cell field call “the yuck factor.”

Recommended reading, especially for those of us less versed in the science of stem cells.

Monday, April 11, 2005

Inside Robert Klein

Reporter Carl Hall of the San Francisco Chronicle has produced a nifty profile of Robert Klein. It has interesting details about his background and explores his motivation and determination.

Here is one quote from the article:

"If there's one thing that I would say about Bob, it's that he makes things happen when other people are trying to stop them from happening," said Chris Miller, a New York marketing executive who has been a friend of Klein's since they both worked on John Tunney's successful 1970 Senate campaign.


"When he decides to help you, you get helped," she said.


The piece notes the criticism that has been directed at Klein.

“Some of the attacks seem motivated as much by discomfort with Klein's hard-charging style as they are by unhappiness with the program. Characteristically, none of it seems to faze Klein.

“During two interviews and many briefer encounters since the November election, Klein makes it clear he has no time for distractions, little patience for Prop. 71 opponents and seemingly infinite faith in his own ability to get the job done,” Hall wrote.

The piece also reported that Klein's grandfather supported Upton Sinclair's California gubernatorial campaign during the Depression, which is a fascinating story by itself.

Profiles like Hall's are quite useful and all too rare in newspapers. They help provide insight into what makes public figures tick. Too often there is an excessive but understandable focus on tangible rules, procedures and actions while the real action is more ambiguous and based on relationships and motivations.

The Conundrums of Conflicts

A man named James Battey wants to be the permanent president of the California stem cell agency. He is quitting his current, very important job because it has new conflict of interest standards that would cost his family “a lot of money.”

By most measures, Battey appears to be qualified to head CIRM. He is head of the National Institutes of Health's stem cell program, but is retiring in September.

He is not alone. Three other high level researchers are leaving the NIH because of the new rules.

The case of James Battey, his colleagues and the NIH illuminates some of the conundrums of conflicts of interest. The situation suggests that conflict policies should start out very restrictive and be eased later, if necessary. It illustrates the very real personal burdens that can laid on top researchers and others. And it demonstrates some of the difficulties in controlling the most insidious sorts of conflicts, the ones arising from a lifetime of belonging, so to speak, to the same club.

Battey said he is leaving the NIH because “the new rules imposed an insurmountable problem for me,” according to a piece in the Washington Post by Michael S. Rosenwald and Rick Weiss.

“I manage a family trust...which supports the education of my father's seven grandchildren, and it contains assets I'm told I'd have to divest. That would cost a lot of money, and I can't do that to my family,” Battey was quoted as saying.


Quite justifiably he may think that the situation is not fair. He once operated under the rules, but then the rules changed through no fault of his own. As a result, the NIH is losing a valued executive and scientist.

An identical situation could occur in California if it has to toughen its conflict standards someplace down the road. It could lose valued employees as a result and then waste time, energy and money replacing them. Better now to be more restrictive than face embittered staff later.

The NIH situation shows how individuals can personally feel the burden of complying with conflict standards, something critics do not always seem to fully understand. It goes beyond consulting arrangements that yield hundreds of thousands of dollars in compensation.

One cancer researcher with the NIH was recently told she could not accept a $200 train ticket to present a paper at a conference for a physician's education group, according to the Post. The researcher said it was embarrassing to cancel her appearance.


The newspaper quoted a legal opinion prepared for a group of senior agency scientists that laid out the scope of the new conflict policy.
"Basically (it) means anything NIHers do outside -- whether getting paid for it or not, from singing in a jazz group to selling art or jewelry, from volunteering at charity organizations to membership in a school or community organization to developing their own small business completely unrelated to biomedical science -- requires prior NIH approval," the memo says.


"We find this very disturbing,” the scientists said. “It is intrusive and scary. It suggests the NIH owns our lives away from work."
The NIH rules additionally touch on the web of relationships that nearly all successful persons build during their careers. The Post said that many NIH employees are barred from holding executive positions with trade or professional organizations, even on a volunteer basis.


One NIH researcher said it could lead to an unpleasant backlash. “We will be cut off, disenfranchised from our academic colleagues.”

Most conflict codes, including the ones now in place at CIRM, can't deal with the ambiguous issues that can arise from the relationships that are built during a career. Sometimes they are formal as in leadership positions in professional organizations. Other times they involve informal or past connections to men and women who have assisted a person during his professional or business life, either financially or with advice or friendship. Sometimes it is training and shared experiences that create a way of thinking that imbues a person's approach to business or science.

The California stem cell agency has built into it a reliance on persons you might call “members of the club” who dominate the Oversight Committee. They bring special expertise, experience and skills to the effort, which is to be valued. They also bring a lifetime of comfortable relationships with other accomplished persons, people they have worked with, rely on and trust. It would be unrealistic not to expect them to go back to these people to seek their help and to help them.

It is also unrealistic to expect codes to catch all of the subtle conflicts and abuses that can and do come up involving such relationships. The best watch dogs, in fact, are other members of the Oversight Committee and CIRM employee peers. They may be the only ones who can stop a breach before it becomes serious enough to become a scandal.
-----
We welcome and will publish comments on CIRM or the failings of this blog. Please send them to djensen@californiastemcellreport.blogspot.com.

Moving Forward

The Oversight Committee of California's stem cell agency is due some positive recognition for enacting a reasonably comprehensive and strict conflict of interest code.

The agency has persevered under much pressure and cranky public attention, dating back to its first meeting only last December. Critics have pummeled the panel. The press has been sharply critical. But rules are now place.

Yes, they are not perfect, but no such effort ever is. More hearings on conflict issues are scheduled for later this year, allowing possibilities for changes and fine-tuning. This is marathon for the Oversight Committee – not a 40-yard dash.

Saturday, April 09, 2005

The Tin Ear of the Private Sector

The will of the people vs. obstructionism, knowledge and expertise vs. public-minded objectivity – some of the constructs bandied about in the debate about conflicts of interest at the California stem cell agency.

There is a certain amount justifiable self-interest as well.


Millionaire Ed Penhoet, vice chairman of the Oversight Committee, told Terri Somers of the San Diego Union Tribune, "I'm spending an enormous amount of time and effort purely in the public interest. I'm not willing to sacrifice the entire rest of my life, which has been in the biotech world, because it doesn't make any sense."

However justified Penhoet's statement may be, it demonstrates one of the differences between the private sector, which has provided many of the Oversight Committee members, and government. A skilled practitioner in the public sector would not have said what Penhoet did. It's impolitic and can be misconstrued. It sems to indicate that he would place his private business above his public responsibilities. And it implies a petulant belief that it is wrong even to ask questions about possible conflicts.

The stem cell agency is continuing its drumbeat that the charges of the critics are meritless because they fly in the face of the will of the people as expressed in November's election. This is a dangerous argument that is not in the best interests of the agency. It places the agency on a collision course with all critics, however warranted their criticism. It has already pushed stem cell agency supporters into hostile positions in which they have formed alliances with those whose greatest desire is close down the agency.


The objectivity vs. expertise argument was also engaged last week as part of the reaction to charges by the Center for Genetics and Society. Somers' story and one by Steve Johnson in the San Jose Mercury News touched on the subject.

Friday, April 08, 2005

Light Coverage of Thursday's Meeting

One of the more interesting things to come out of Thursday's meeting of the California stem cell agency is the apparent lack of media coverage.

A quick check showed only two major newspapers with their own stories and no story from The Associated Press, which feeds coverage to thousands of outlets worldwide.

The San Diego Union Tribune (Terri Somers) and The Sacramento Bee (Laura Mecoy) had staff written stories on the approval of the conflict of interest codes. The Los Angeles Times, the San Francisco Chronicle and the San Jose Mercury News carried none, based on a look at their web sites. A search of the Internet turned up no other stories in California newspapers, although there may have been some.

There are a couple of reasons for this. One could be deadline problems. Reporters may have been there but filed stories too late to be placed in the paper. The other may be that the novelty is wearing thin. Newspapers only skim the top of most events. They turn away from issues that seem to be getting old, even if they are fundamentally important. And the conflict of interest flap has been written about repeatedly since the agency's first meeting in December.

We may yet see additional stories from this week's meeting, perhaps on Saturday or Sunday.

Search This Blog